|
|
Prepublished online as a Blood First Edition Paper on October 17, 2002; DOI 10.1182/blood-2002-08-2441.
Submitted August 22, 2002
Accepted October 3, 2002
Prognostic value of angiogenesis in solitary bone plasmacytoma
Shaji Kumar, Rafael Fonseca, Angela Dispenzieri, Martha Q Lacy, John A Lust, Linda Wellik, Thomas E Witzig, Morie A Gertz, Robert A Kyle, Philip R Greipp, and S Vincent Rajkumar*
Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
* Corresponding author; email: rajkumar.vincent{at}mayo.edu.
Angiogenesis plays an important role in the biology of multiple myeloma (MM) and has prognostic importance in this disease. Solitary plasmacytoma is a localized plasma cell malignancy that progresses to MM in a significant number of patients. We examined if angiogenesis is increased in solitary plasmacytoma and if it can help identify patients likely to progress to myeloma. We studied angiogenesis in plasmacytoma biopsy samples and bone marrow biopsies from 25 patients. High-grade angiogenesis was present in 64% of plasmacytomas. In contrast, bone marrow angiogenesis was low in all patients. Patients with high-grade angiogenesis in the plasmacytoma sample were more likely to progress to myeloma and had a shorter progression free survival, compared to patients with low grade angiogenesis (P=0.02). Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Lin, A. Luciani, K. Belhadj, P. Maison, A. Vignaud, J.-F. Deux, P. Zerbib, F. Pigneur, E. Itti, H. Kobeiter, et al.
Patients with Plasma Cell Disorders Examined at Whole-Body Dynamic Contrast-enhanced MR Imaging: Initial Experience
Radiology,
March 1, 2009;
250(3):
905 - 915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Dingli, R. A. Kyle, S. V. Rajkumar, G. S. Nowakowski, D. R. Larson, J. P. Bida, M. A. Gertz, T. M. Therneau, L. J. Melton III, A. Dispenzieri, et al.
Immunoglobulin free light chains and solitary plasmacytoma of bone
Blood,
September 15, 2006;
108(6):
1979 - 1983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar, A. Dispenzieri, and R. A. Kyle
Monoclonal Gammopathy of Undetermined Significance, Waldenstrom Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment
Mayo Clin. Proc.,
May 1, 2006;
81(5):
693 - 703.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Podar and K. C. Anderson
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Blood,
February 15, 2005;
105(4):
1383 - 1395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar
MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management
Hematology,
January 1, 2005;
2005(1):
340 - 345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumar, T. E. Witzig, M. Timm, J. Haug, L. Wellik, T. K. Kimlinger, P. R. Greipp, and S. V. Rajkumar
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression
Blood,
August 15, 2004;
104(4):
1159 - 1165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Asosingh, H. De Raeve, E. Menu, I. Van Riet, E. Van Marck, B. Van Camp, and K. Vanderkerken
Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity
Blood,
April 15, 2004;
103(8):
3131 - 3137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
